NextCure Q3 net loss narrows after restructuring
NXTC•NextCure reported a third-quarter net loss of $6.85 million, narrowing from a year earlier as restructuring reduced research and development expenses. The company is advancing a merger with Avere Therapeutics backed by $820 million in committed financing.
1. Quarterly results
NextCure reported a third-quarter net loss of $6.85 million and an operating loss of $6.92 million. Loss per basic share was $1.29. Lower research and development expenses reflected restructuring, lower personnel and lab costs, and asset sales; merger-related legal and professional fees increased general and administrative expenses.
2. Merger and financing
NextCure is advancing a merger with Avere Therapeutics, backed by $820 million in committed financing. The combined company is expected to operate as Avere and trade on Nasdaq as AVRX after the merger. The financing is expected to support AVR-001 development and future operations. A stockholder vote is scheduled for Dec. 9, 2026, and completion is subject to approval and other conditions.
